Apollomics (APLM) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apollomics (APLM) has outperformed Spero Therapeutics (SPRO) over the past year, gaining 18.2% versus a loss of 50.0%. Spero Therapeutics is the larger company by market cap ($69.9 million vs $62.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | SPRO |
|---|---|---|
| Share price | $21.50 | $1.20 |
| Market cap | $62.67M | $69.88M |
| 1-day change | -0.92% | +5.26% |
| YTD return | +16.50% | -51.07% |
| 1-year return | +18.16% | -50.00% |
| 5-year return | — | -93.30% |
| P/E ratio (TTM) | — | 8.57 |
| EPS (TTM) | $-7.57 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.12 | $3.08 |
| 52-week low | $10.01 | $1.08 |
| Distance from 52-week high | -48.96% | -61.04% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +316.67% |
| Average volume | 21.69K | 1.20M |
| Shares outstanding | 2.91M | 58.23M |
| Employees | 14 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed SPRO by 68.2 percentage points over the past year.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
APLM vs SPRO FAQ
Which is bigger, Apollomics or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $69.88M compared with $62.67M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or SPRO?
APLM returned +18.16% over the past 12 months, compared with -50.00% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.